- Keiji Wada, MD, PhD
- under construction
- Yu-ichi Goto, MD, PhD
- Dr. Goto is currently the Vice Director General of the Translational Medical Center (2011-present). After obtaining his MD degree at Hokkaido University School of Medicine (1976-1982), he worked as a resident in the Department of Pediatrics, Hokkaido University School of Medicine (1982-1988). He completed a postdoctoral fellowship at Stanford University School of Medicine (1990-1992) and has been working for the National Center of Neurology and Psychiatry (NCNP) since 1998. He is currently also Director of the Department of Mental Retardation and Birth Defect Research at NCNP’s National Institute of Neuroscience (2000-present).
- En Kimura, MD, PhD
- Dr. Kimura is the Chief of the Extra Early Exploratory Clinical Trial Unit (EEECU) at the Translational Medical Center. The EEECU supports Cluster Ward at NCNP’s National Center Hospital as well as Remudy, which runs three official national registries for dystrophinopathy, GNE myopathy, and myotonic dystrophy in collaboration with the TREAT-NMD Alliance. He has been a member of the TREAT-NMD Global Registry Oversight Committee since 2012. His research interests range from basic biology to clinical development and regulatory sciences. As a clinical neurologist and researcher of neuromuscular diseases, he focuses particularly on developing new gene and cell therapies for muscular dystrophy and conducts worldwide epidemiological research into rare neuromuscular diseases.
- Harumasa Nakamura, MD
- Dr. Nakamura is Section Chief of the Department of Clinical Research Support at the Translational Medical Center and Section Chief of the Clinical Research/Trial Promotion Section, Department of Clinical Research Promotion at the National Center Hospital. Dr. Nakamura is a neurologist who is certified to practice as a specialist of clinical neurology by the Japanese Society of Neurology. He specializes in the treatment of neuromuscular disorders, neurodegenerative disorders, and neuroimmunological disorders at NCNP. He previously worked as a medical reviewer for the Office of New Drug 3 at the Pharmaceuticals and Medical Devices Agency (2005-2008, 2012-2014) and was a member of the PMDA’s Orphan Medicine Working Group. His main research interests are pharmaceutical medicine, regulatory science, and drug development for orphan diseases.